These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 11758556)

  • 1. The potential for self-interested behavior by pharmaceutical manufacturers through vertical integration with pharmacy benefit managers: the need for a new regulatory approach.
    Mitchell EL
    Food Drug Law J; 1999; 54(1):151-83. PubMed ID: 11758556
    [No Abstract]   [Full Text] [Related]  

  • 2. The FDA's regulation of pharmaceutical communications in the context of managed care: a suggested approach.
    Kuhlik BN
    Food Drug Law J; 1995; 50(1):23-48. PubMed ID: 10342984
    [No Abstract]   [Full Text] [Related]  

  • 3. Risky business: proposed reform of the antitrust laws as applied to health care provider networks.
    Marjancik N
    Am J Law Med; 1998; 24(1):59-87. PubMed ID: 9607104
    [No Abstract]   [Full Text] [Related]  

  • 4. The legal framework for effective competition.
    Berenson RA; Hastings DA; Kopit WG
    Baxter Health Policy Rev; 1996; 2():235-65. PubMed ID: 11066262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The response to health care reform by the pharmaceutical industry.
    Krulwich AS
    Food Drug Law J; 1995; 50(1):1-22. PubMed ID: 10342983
    [No Abstract]   [Full Text] [Related]  

  • 6. A whole new world?: pharmaceutical responses to the managed care revolution.
    Balto DA
    Food Drug Law J; 1997; 52(1):83-98. PubMed ID: 10346712
    [No Abstract]   [Full Text] [Related]  

  • 7. Too big? Caremark, AdvancePCS getting close look from feds.
    Becker C
    Mod Healthc; 2004 Jan; 34(2):14, 16. PubMed ID: 14959629
    [No Abstract]   [Full Text] [Related]  

  • 8. Disease management: partnering for better patient care.
    Sylvestri MF; Marro EP
    Med Interface; 1996 Jul; 9(7):100-4. PubMed ID: 10159274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmaceutical manufacturers ... leaving tradition behind and forging new managed care alliances.
    Barnett AA
    State Health Care Am; 1995; ():41-6. PubMed ID: 10168072
    [No Abstract]   [Full Text] [Related]  

  • 10. Limits placed on PHOs by antitrust rulings, transitional structure for integration.
    Health Care Strateg Manage; 1995 Nov; 13(11):14-5. PubMed ID: 10151858
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmaceutical industry and payer partnerships: legal update.
    Goldstein WC
    Manag Care; 2001 Sep; 10(9 Suppl):5-6; discussion 9-12. PubMed ID: 11729439
    [No Abstract]   [Full Text] [Related]  

  • 12. Point/counterpoint. The HMO pharmacy benefit. In-house pharmacy administration: the benefits of integration.
    Penna P
    HMO; 1995; 36(4):56, 58-9. PubMed ID: 10166487
    [No Abstract]   [Full Text] [Related]  

  • 13. Integration options.
    Williams L
    J Health Hosp Law; 1996; 29(2):88-96, 106. PubMed ID: 10160177
    [No Abstract]   [Full Text] [Related]  

  • 14. Strength in numbers or antitrust trouble?
    Bianculli JL
    Contemp Longterm Care; 1997 May; 20(5):60-1. PubMed ID: 10167546
    [No Abstract]   [Full Text] [Related]  

  • 15. Working with PBMs (pharmacy benefit managers).
    Peterson C
    Healthplan; 1999; 40(2):83-6, 88-9. PubMed ID: 10537477
    [No Abstract]   [Full Text] [Related]  

  • 16. The tripartite regulation of America's health services.
    Weil TP; Jorgensen NE
    Spectrum; 1996; 69(1):39-43. PubMed ID: 10156001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulating manufacturer-affiliated communication in the information age.
    Schulman KA; Abernethy DR; Rathore SS; Woosley RL
    Clin Pharmacol Ther; 1999 Jun; 65(6):593-7. PubMed ID: 10391664
    [No Abstract]   [Full Text] [Related]  

  • 18. How well does your PBM perform?
    McCarthy R
    Bus Health; 1999 Jan; 17(1):24-9. PubMed ID: 10345211
    [No Abstract]   [Full Text] [Related]  

  • 19. Competition and antitrust enforcement in the changing pharmaceutical marketplace.
    Whitener MD
    Food Drug Law J; 1995; 50(2):301-7. PubMed ID: 10342998
    [No Abstract]   [Full Text] [Related]  

  • 20. Managed care cost containment involving prescription drugs. American Medical Association, Council on Ethical and Judicial Affairs.
    Food Drug Law J; 1998; 53(1):25-34. PubMed ID: 11795334
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.